AbCellera

AbCellera Biologics Inc.
Company typePublic
Nasdaq: ABCL
IndustryContract Research Organization
Founded2012 (2012)
HeadquartersVancouver, British Columbia
Revenue38 million (2023)
US $-163 million (2024)
Number of employees
386 (2021)
Websiteabcellera.com

AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization (CRO) that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.